Search

Acute Lymphocytic Leukemia: impressive results with the monoclonal antibody blinatumomab

The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant.

Read more

Selected EMA news

February 2025New medicines recommended for approval
Dyrupeg (pegfilgrastim) – biosimilar
Treatment to shorten the duration of neutropenia and help prevent febrile neutropenia after cytotoxic chemotherapy

Eltrombopag Accord (eltrombopag) – generic
Treatment of primary immune thrombocytopenia and thrombocytopenia associated with chronic hepatitis C
New information on…

Read more

Highlights of Past EHA - Cairo 2017

Dates: September 14 - 15, 2017
Location: Cairo, Egypt
Chairs: 
Prof Azza Kamel, Secretary General, Egyptian Society of Hematology and Research (ESHR)
Prof Amal El-Beshlawy, Vice President, Egyptian Society of Hematology and Research (ESHR)
Prof John Gribben, President elect, European Hematology Association (EHA)
Prof Mohamad Qari, President, Pan…

Read more

EHA-AHA Tutorial on Biology and Management of Myeloid Malignancies

In collaboration with the Armenian Hematology Association. Dates: October 20-21, 2017
Location: Yerevan, Armenia
Chairs: S Daghbashyan, JJ Kiladjian & P Fenaux
Language: English (with simultaneous translation to Russian)

Online registration is closed.

Read more

Highlights of Past EHA (HOPE) Cairo 2018

EHA returned to Cairo with the 3rd edition of the Highlights of Past EHA (HOPE). The meeting was organized in partnership with regional and national societies in the Middle East and North Africa.

Read more